(Q36325601)

13 August 2017

1 reference

title

PSA testing: an evolving relationship with prostate cancer screening (English)

1 reference

prostate cancer screening

13 August 2017

1 reference

1 reference

Constantinou J

1

1 reference

13 August 2017

Feneley MR

series ordinal

2

1 reference

13 August 2017

publication date

1 January 2006

1 reference

Prostate Cancer and Prostatic Diseases

13 August 2017

published in

1 reference

13 August 2017

volume

9

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

6-13

1 reference

Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Localised prostatic cancer: management and detection issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Screening for prostate cancer with prostate-specific antigen. An examination of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Today men with prostate cancer have larger prostates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Population-based study of long-term survival in patients with clinically localised prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

International trends in prostate-cancer mortality in the "PSA ERA".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

MISCAN: estimating lead-time and over-detection by simulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Continence, potency and morbidity after radical perineal prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Quality of life after radical prostatectomy or watchful waiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

uPM3, a new molecular urine test for the detection of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Transrectal colour Doppler ultrasonography for quantifying angiogenesis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

Prostate cancer epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

7 January 2021

Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

7 January 2021

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

7 January 2021

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

7 January 2021

Age-specific reference ranges for serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

7 January 2021

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

7 January 2021

Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

7 January 2021

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

7 January 2021

The development of erectile dysfunction in men treated for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

7 January 2021

Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500838

7 January 2021

Identifiers

DOI

10.1038/SJ.PCAN.4500838

1 reference

Dimensions Publication ID

13 August 2017

1034143420

0 references

1 reference